Topics

Roche’s satralizumab succeeds in second positive study in rare CNS disease

07:11 EDT 12 Sep 2019 | Pharmafile

In a second pivotal Phase 3 study of Roche’s satralizumab, the drug showed itself to significantly reduce relapse risk for neuromyelitis optica spectrum disorder (NMOSD), a rare central nervous system disease.

NMOSD is a rare, lifelong and debilitating autoimmune disease of the central nervous system that primarily damages the optic nerves and spinal cord, causing blindness, muscle weakness and paralysis.

read more

Original Article: Roche’s satralizumab succeeds in second positive study in rare CNS disease

NEXT ARTICLE

More From BioPortfolio on "Roche’s satralizumab succeeds in second positive study in rare CNS disease"

Quick Search

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Autoimmune Disorders
Autoimmune disorders are conditions that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune disorders. Normally the immune system's white blood cells help protect ...